Annals of Surgical Oncology

, Volume 18, Issue 7, pp 1972–1979 | Cite as

Liver Resection and Ablation for Metastatic Adrenocortical Carcinoma

  • R. Taylor Ripley
  • Clinton D. Kemp
  • Jeremy L. Davis
  • Russell C. Langan
  • Richard E. Royal
  • Steven K. Libutti
  • Seth M. Steinberg
  • Bradford J. Wood
  • Udai S. Kammula
  • Tito Fojo
  • Itzhak Avital
Hepatobiliary Tumors

Abstract

Background

Adrenocortical carcinoma (ACC) is a rare disease without effective chemotherapy treated most appropriately with resection. The aim of this study was to evaluate our experience with liver resection for metastatic ACC.

Methods

This study is a retrospective review of patients who underwent liver resection or radiofrequency ablation (RFA) for ACC from 1979 to 2009.

Results

A total of 27 patients were identified. Of the 27, 19 underwent liver resection. Of the 19, 10 had a single liver lesion, and 18 of 19 were rendered free of disease in the liver, although only 11 of 19 were rendered completely free of disease because of extrahepatic disease (EHD). Of the 19, 13 had synchronous EHD. Also, 6 of 17 remained disease free in the liver at a median follow-up of 6.2 years (status of 2 of 19 was unknown). Of the 27 patients, 8 underwent RFA, 7 of 8 became free of disease in the liver, and 5 of 7 had EHD. No patients responded to prior chemotherapy. Median overall survival and survival of patients who underwent liver resection or RFA were both 1.9 years (0.2–12 + years); 5-year actuarial survivals were 29% and 29%, respectively. Disease-free interval (DFI) greater than 9 months from primary resection was associated with longer survival (median 4.1 vs 0.9 years; P = .013).

Conclusions

This study is a tertiary institution series of liver resection and RFA for ACC. Given the lack of effective systemic treatment options and the safety of resection and ablation, liver resection or RFA may be considered in selected patients with ACC metastatic to the liver especially with a long DFI.

Notes

Acknowledgment

Aarti Mathur, MD for assistance with data collection.

References

  1. 1.
    Vaughan ED Jr. Diseases of the adrenal gland. Med Clin North Am. 2004;88:443–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Roman S. Adrenocortical carcinoma. Curr Opin Oncol. 2006;18:36–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996;119:161–70.Google Scholar
  5. 5.
    Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery. 1995;118:1090–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004;60:273–87.CrossRefGoogle Scholar
  9. 9.
    Trainer PJ, Besser M. Cushing’s syndrome. Therapy directed at the adrenal glands. Endocrinol Metab Clin North Am. 1994;23:571–84.Google Scholar
  10. 10.
    Dickstein G, Shechner C, Nativ O. Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med. 2007;357:1257–8; author reply 1259.PubMedGoogle Scholar
  11. 11.
    Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Grubbs E, Lee JE. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:5847; author reply 5848.PubMedCrossRefGoogle Scholar
  13. 13.
    Favia G, Lumachi F, Carraro P, D’Amico DF. Adrenocortical carcinoma. Our experience. Minerva Endocrinol. 1995;20:95–9.PubMedGoogle Scholar
  14. 14.
    Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, et al. Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol. 2007;37:108–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D’Angelica M, Harrison LE, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg. 2005;241:269–76.PubMedCrossRefGoogle Scholar
  16. 16.
    Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg. 1991;126:457–61.PubMedGoogle Scholar
  17. 17.
    Rodgers SE, Evans DB, Lee JE, Perrier ND. Adrenocortical carcinoma. Surg Oncol Clin N Am. 2006;15:535–53.Google Scholar
  18. 18.
    Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. Surgery. 1986;100:1170–7.PubMedGoogle Scholar
  19. 19.
    Manetti L, Bogazzi F, Giovannetti C, Rafaelli V, Genovesi M, Pellegrini G, et al., Changes in coagulation indexes and occurrences of venous thromboembolism in patients with Cushing’s syndrome: Results from a prospective study before and after surgery. Eur J Endocrinol. 2010;163:783–91.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • R. Taylor Ripley
    • 1
  • Clinton D. Kemp
    • 1
  • Jeremy L. Davis
    • 1
  • Russell C. Langan
    • 1
  • Richard E. Royal
    • 1
  • Steven K. Libutti
    • 1
  • Seth M. Steinberg
    • 2
  • Bradford J. Wood
    • 3
  • Udai S. Kammula
    • 1
  • Tito Fojo
    • 4
  • Itzhak Avital
    • 1
  1. 1.Surgery BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
  2. 2.Biostatistics and Data Management Section, Office of the Clinical DirectorNational Cancer Institute, National Institutes of HealthBethesdaUSA
  3. 3.Department of Diagnostic RadiologyNational Cancer Institute, National Institutes of HealthBethesdaUSA
  4. 4.Medicine Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations